Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.

Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff VK.

Nat Med. 2011 Nov 20;17(12):1652-6. doi: 10.1038/nm.2579.

PMID:
22101764
2.

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.

Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators.

Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Erratum in: Lancet Neurol. 2013 Nov;12(11):1042. Carbonell, J G [corrected to Gamez, J].

PMID:
24067398
3.

KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.

Gribkoff VK, Bozik ME.

CNS Neurosci Ther. 2008 Fall;14(3):215-26. doi: 10.1111/j.1755-5949.2008.00048.x. Review.

PMID:
18801114
4.

Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects.

Bozik ME, Mather JL, Kramer WG, Gribkoff VK, Ingersoll EW.

J Clin Pharmacol. 2011 Aug;51(8):1177-85. doi: 10.1177/0091270010379412. Epub 2010 Oct 19.

PMID:
20959524
5.

Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.

Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14(1):44-51. doi: 10.3109/17482968.2012.723723. Epub 2012 Sep 17.

PMID:
22985432
6.

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Miller RG, Mitchell JD, Lyon M, Moore DH.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Review.

PMID:
13129806
7.

Quantitative strength testing in ALS clinical trials.

Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, Cudkowicz M.

Neurology. 2016 Aug 9;87(6):617-24. doi: 10.1212/WNL.0000000000002941. Epub 2016 Jul 6.

8.

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.

Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, Cudkowicz ME, van den Berg LH, Mather J, Petzinger T Jr, Archibald D.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):406-13. doi: 10.3109/21678421.2014.943672. Epub 2014 Aug 15.

PMID:
25125035
9.

A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.

Saccà F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Perrotta G, Carotenuto B, Marsili A, Palma V, De Michele G, Brunetti A, Brescia Morra V, Filla A, Salvatore M.

J Neurol. 2012 Jan;259(1):132-8. doi: 10.1007/s00415-011-6146-2. Epub 2011 Jun 25.

PMID:
21706151
10.

Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.

Elia AE, Lalli S, Monsurrò MR, Sagnelli A, Taiello AC, Reggiori B, La Bella V, Tedeschi G, Albanese A.

Eur J Neurol. 2016 Jan;23(1):45-52. doi: 10.1111/ene.12664. Epub 2015 Feb 9. Erratum in: Eur J Neurol. 2017 Apr;24(4):659.

11.

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, Clawson L, Haas L, Rothstein JD.

Amyotroph Lateral Scler. 2010 May 3;11(3):266-71. doi: 10.3109/17482960903307805.

PMID:
19961264
12.
13.

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.

Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, Kaufman P, Conwit RA, Schoenfeld D, Shefner J, Cudkowicz M; Northeast and Canadian Amyotrophic Lateral Sclerosis consortia.

Lancet Neurol. 2010 May;9(5):481-8. doi: 10.1016/S1474-4422(10)70068-5. Epub 2010 Apr 1.

14.

Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].

Al-Chalabi A, Shaw PJ, Young CA, Morrison KE, Murphy C, Thornhill M, Kelly J, Steen IN, Leigh PN; UKMND-LiCALS.

BMC Neurol. 2011 Sep 21;11:111. doi: 10.1186/1471-2377-11-111.

15.

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V.

Lancet. 1996 May 25;347(9013):1425-31.

PMID:
8676624
16.

Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients.

Nagata E, Ogino M, Iwamoto K, Kitagawa Y, Iwasaki Y, Yoshii F, Ikeda JE; ALS Consortium Investigators.

PLoS One. 2016 Feb 24;11(2):e0149509. doi: 10.1371/journal.pone.0149509. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0152845.

17.

A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.

Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, Shaw PJ, Pruss RM, Cuvier V, Meininger V; Mitotarget study group.

Eur J Neurol. 2014 Mar;21(3):529-36. doi: 10.1111/ene.12344. Epub 2014 Jan 21.

PMID:
24447620
18.

A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.

Shibuya K, Misawa S, Kimura H, Noto Y, Sato Y, Sekiguchi Y, Iwai Y, Mitsuma S, Beppu M, Watanabe K, Fujimaki Y, Tsuji Y, Shimizu T, Mizuno T, Nakagawa M, Sawaguchi K, Hanaoka H, Kuwabara S.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):353-8. doi: 10.3109/21678421.2015.1038277. Epub 2015 May 11.

PMID:
25960085
19.

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.

Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, Hager C, Ludolph AC, Becker G, Osterhage J, Jost WH, Schrank B, Stein C, Kostopulos P, Lubik S, Wekwerth K, Dengler R, Troeger M, Wuerz A, Hoge A, Schrader C, Schimke N, Krampfl K, Petri S, Zierz S, Eger K, Neudecker S, Traufeller K, Sievert M, Neundörfer B, Hecht M; German vitamin E/ALS Study Group.

J Neural Transm (Vienna). 2005 May;112(5):649-60. Epub 2004 Oct 27.

PMID:
15517433
20.

R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.

Wang H, Larriviere KS, Keller KE, Ware KA, Burns TM, Conaway MA, Lacomis D, Pattee GL, Phillips LH 2nd, Solenski NJ, Zivkovic SA, Bennett JP Jr.

Amyotroph Lateral Scler. 2008 Feb;9(1):50-8. doi: 10.1080/17482960701791234.

PMID:
18270879

Supplemental Content

Support Center